We hypothesize that mutations in different domains of GATA2 may have distinct impact on clinico-biological features and outcomes in AML patients, like IDH2 mutations in which IDH2 R172 is associated with gene mutations and clinical outcomes different from other IDH mutations14. The gene discussed is GATA2; the disease is acute myeloid leukemia.